SHELLY CLARY: Open Payments
NPI 1437557287 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 46 payments from 20 companies in 2025. Trend: 2023 $2,197 · 2024 $1,216 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $172 |
| AstraZeneca Pharmaceuticals LP | 2 | $160 |
| Abbott Laboratories | 4 | $69 |
| ABBVIE INC. | 4 | $66 |
| Dexcom, Inc. | 4 | $66 |
| PFIZER INC. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Boston Scientific Corporation | 2 | $58 |
| Lilly USA, LLC | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
Products named: Ozempic, AIRSUPRA, REXULTI, FREESTYLE LIBRE 3, Dexcom G6 Transmitter, NURTEC ODT, CAPLYTA, General - Pain Management.
Industry payments across GA — which companies pay providers there.
